The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: a cross sectional study
Abstract Background Following reduction of public health and social measures concurrent with SARS-CoV-2 Omicron emergence in late 2021 in Australia, COVID-19 case notification rates rose rapidly. As rates of direct viral testing and reporting dropped, true infection rates were most likely to be underestimated.Objective To better understand infection rates and immunity in this population, we aimed to estimate SARS-CoV-2 seroprevalence in Australians aged 0-19 years.Methods We conducted a national cross sectional serosurvey from June 1, 2022, to August 31, 2022, in children aged 0-19 years undergoing an anesthetic procedure at eight tertiary pediatric hospitals. Parents or guardians of children and adolescents under 18 years provided written consent and participants aged 18-19 years provided their own consent. Participant questionnaires were administered, and blood samples tested using the Roche Elecsys Anti-SARS-CoV-2 total spike and nucleocapsid antibody assays. S and N seroprevalence adjusted for geographic and socioeconomic imbalances in the participant sample compared to the Australian population was estimated using multilevel regression and poststratification within a Bayesian framework.Results Blood was collected from 2,046 participants (median age: 6.6 years). Adjusted seroprevalence of spike-antibody was 92.1 % (95% credible interval (CrI) 91.0-93.3%) and nucleocapsid-antibody was 67.0% (95% CrI 64.6-69.3). In unvaccinated children spike and nucleocapsid antibody seroprevalences were 84.2% (95% CrI 81.9-86.5) and 67.1% (95%CrI 64.0-69.8), respectively. Seroprevalence increased with age but was similar across geographic distribution and socioeconomic quintiles.Conclusion Most Australian children and adolescents aged 0-19 years, across all jurisdictions were infected with SARS-CoV-2 by August 2022, suggesting rapid and uniform spread across the population in a very short time period. High seropositivity in unvaccinated children informed COVID-19 vaccine recommendations in Australia.Funding Australian Government Department of Health and Aged Care..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 07. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2024.03.03.24303672 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI042711398 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI042711398 | ||
| 003 | DE-627 | ||
| 005 | 20240308091358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240306s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.03.03.24303672 |2 doi | |
| 035 | |a (DE-627)XBI042711398 | ||
| 035 | |a (biorXiv)10.1101/2024.03.03.24303672 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Koirala, Archana |e verfasserin |0 (orcid)0000-0002-2567-8825 |4 aut | |
| 245 | 1 | 0 | |a The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: a cross sectional study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Following reduction of public health and social measures concurrent with SARS-CoV-2 Omicron emergence in late 2021 in Australia, COVID-19 case notification rates rose rapidly. As rates of direct viral testing and reporting dropped, true infection rates were most likely to be underestimated.Objective To better understand infection rates and immunity in this population, we aimed to estimate SARS-CoV-2 seroprevalence in Australians aged 0-19 years.Methods We conducted a national cross sectional serosurvey from June 1, 2022, to August 31, 2022, in children aged 0-19 years undergoing an anesthetic procedure at eight tertiary pediatric hospitals. Parents or guardians of children and adolescents under 18 years provided written consent and participants aged 18-19 years provided their own consent. Participant questionnaires were administered, and blood samples tested using the Roche Elecsys Anti-SARS-CoV-2 total spike and nucleocapsid antibody assays. S and N seroprevalence adjusted for geographic and socioeconomic imbalances in the participant sample compared to the Australian population was estimated using multilevel regression and poststratification within a Bayesian framework.Results Blood was collected from 2,046 participants (median age: 6.6 years). Adjusted seroprevalence of spike-antibody was 92.1 % (95% credible interval (CrI) 91.0-93.3%) and nucleocapsid-antibody was 67.0% (95% CrI 64.6-69.3). In unvaccinated children spike and nucleocapsid antibody seroprevalences were 84.2% (95% CrI 81.9-86.5) and 67.1% (95%CrI 64.0-69.8), respectively. Seroprevalence increased with age but was similar across geographic distribution and socioeconomic quintiles.Conclusion Most Australian children and adolescents aged 0-19 years, across all jurisdictions were infected with SARS-CoV-2 by August 2022, suggesting rapid and uniform spread across the population in a very short time period. High seropositivity in unvaccinated children informed COVID-19 vaccine recommendations in Australia.Funding Australian Government Department of Health and Aged Care. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a McRae, Jocelynne |0 (orcid)0000-0001-7234-509X |4 aut | |
| 700 | 1 | |a Britton, Philip N |0 (orcid)0000-0002-2993-6000 |4 aut | |
| 700 | 1 | |a Downes, Marnie |4 aut | |
| 700 | 1 | |a Prasad, Shayal A |4 aut | |
| 700 | 1 | |a Nicholson, Suellen |0 (orcid)0000-0001-6585-7150 |4 aut | |
| 700 | 1 | |a Winkler, Noni E |4 aut | |
| 700 | 1 | |a O’Sullivan, Matthew V N |4 aut | |
| 700 | 1 | |a Gondalwala, Fatima |4 aut | |
| 700 | 1 | |a Castellano, Cecile |4 aut | |
| 700 | 1 | |a Carey, Emma |4 aut | |
| 700 | 1 | |a Hendry, Alexandra |4 aut | |
| 700 | 1 | |a Crawford, Nigel |4 aut | |
| 700 | 1 | |a Wadia, Ushma |4 aut | |
| 700 | 1 | |a Richmond, Peter |0 (orcid)0000-0001-7562-7228 |4 aut | |
| 700 | 1 | |a Marshall, Helen S |4 aut | |
| 700 | 1 | |a Clark, Julia E |0 (orcid)0000-0001-7746-0599 |4 aut | |
| 700 | 1 | |a Francis, Joshua R |4 aut | |
| 700 | 1 | |a Carr, Jeremy |4 aut | |
| 700 | 1 | |a Bartlett, Adam |0 (orcid)0000-0002-7532-9316 |4 aut | |
| 700 | 1 | |a McMullan, Brendan |4 aut | |
| 700 | 1 | |a Skowno, Justin |4 aut | |
| 700 | 1 | |a Hannah, Donald |4 aut | |
| 700 | 1 | |a Davidson, Andrew |4 aut | |
| 700 | 1 | |a von Ungern-Sternberg, Britta S |4 aut | |
| 700 | 1 | |a Lee-Archer, Paul |4 aut | |
| 700 | 1 | |a Burgoyne, Laura L |4 aut | |
| 700 | 1 | |a Waugh, Edith B |0 (orcid)0000-0002-8685-5389 |4 aut | |
| 700 | 1 | |a Carlin, John B |4 aut | |
| 700 | 1 | |a Naing, Zin |4 aut | |
| 700 | 1 | |a Kerly, Nicole |4 aut | |
| 700 | 1 | |a McMinn, Alissa |4 aut | |
| 700 | 1 | |a Hunter, Guillian |4 aut | |
| 700 | 1 | |a Heath, Christine |4 aut | |
| 700 | 1 | |a D’Angelo, Natascha |4 aut | |
| 700 | 1 | |a Finucane, Carolyn |4 aut | |
| 700 | 1 | |a Francis, Laura A |4 aut | |
| 700 | 1 | |a Dougherty, Sonia |4 aut | |
| 700 | 1 | |a Rawlinson, William |4 aut | |
| 700 | 1 | |a Karapanagiotidis, Theo |4 aut | |
| 700 | 1 | |a Cain, Natalie |4 aut | |
| 700 | 1 | |a Brizuela, Rianne |4 aut | |
| 700 | 1 | |a Blyth, Christopher C |0 (orcid)0000-0003-2017-0683 |4 aut | |
| 700 | 1 | |a Wood, Nicholas |4 aut | |
| 700 | 1 | |a Macartney, Kristine |0 (orcid)0000-0002-4675-0232 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 07. März |
| 773 | 1 | 8 | |g year:2024 |g day:07 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.03.03.24303672 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 07 |c 03 | ||